project

CoV-SigN

Identification of novel inhibitors against emerging human coronaviruses SARS-CoV and MERS-CoV from host cellular transcriptionic signatures
French National Research Agency (ANR)
  • Funder: French National Research Agency (ANR)Project code: ANR-14-CE15-0008
  • Funder Contribution: 417,638 EUR
Description
In 2012, a novel human coronavirus (MERS-CoV) was identified in the Middle East as the causative agent of a severe acute and/or fatal respiratory syndrome. Since its identification, it has been responsible for 211 laboratory-confirmed cases including 88 deaths. Most cases are sporadic but human-to-human transmission has been documented both in hospital settings and community clusters. Emergence of this new coronavirus in humans raises concerns about a possible widespread outbreak, similar to the one previously caused by SARS-CoV in 2003. Control of such emerging viral pathogens constitutes a major public health issue. However, despite the urgent need for efficie...
Description
In 2012, a novel human coronavirus (MERS-CoV) was identified in the Middle East as the causative agent of a severe acute and/or fatal respiratory syndrome. Since its identification, it has been responsible for 211 laboratory-confirmed cases including 88 deaths. Most cases are sporadic but human-to-human transmission has been documented both in hospital settings and community clusters. Emergence of this new coronavirus in humans raises concerns about a possible widespread outbreak, similar to the one previously caused by SARS-CoV in 2003. Control of such emerging viral pathogens constitutes a major public health issue. However, despite the urgent need for efficie...
Any information missing or wrong?Report an Issue